Pharmacoeconomics: theory and practice
№2, 2014, Vol.2
Summary: The analysis of insulin agents’ consumption in the pharmaceutical market of Ukraine as of the data of years 2008-2012 has been carried out using the АТС/DDD methodology in terms of DDDS/1000 of persons/day. The low level of consumption, compared to the European countries, as well as its reduction, compared to the data of 2008, has been determined. The structural analysis has shown low insulin consumption. The highest consumption level has been determined for the human insulin agent. The data on provision of PD-1 patients with insulin medications, without consideration of PD-2 patients’ consumption, evidence the inconsistence of the consumption volume with PD-1 case rate. Key words: consumption analysis, insulin preparations, pancreatic diabetes
Summary The pharmacoeconomic study on the medicine regimens of diabetes mellitus (DM) type 2 was conducted with the purpose of their improvement. The research was based on the retrospective analysis of 599 medical histories of patients of type 2 diabetes. These patients were treated at the Vinnytsia Regional Clinical Endocrinology Clinic in 2011-2012. The studies of medicine regimens were performed by the «cost-effectiveness» analysis. We have found that the scheme of pharmacotherapy metformin+gliclazide has cost-effective advantage over the scheme pharmacotherapy metformin+glimepiride.
Summary: The pharmacoeconomic evaluation of the treatment of infectious bacterial conjunctivitis by the medicaments of fluoroquinolones: moxifloxacin (Vigamox), levofloxacin (Oftaquix, Signicef), ciproflaxacinum (Cipromed) and ofloxacin (Floksal) have been conducted in regards to the conditions of the Russian health care system. The results of analysis of the «cost-effectiveness» have shown that the medicament of moxifloxacin (Vigamox) is dominant over the comparator medicaments, requiring the least cost to achieve the successful treatment of bacterial conjunctivitis per patient. The «budget impact» analysis have illustrated that the replacement of the fluoroquinolone medicament of the II-III generation for the moxifloxacin (Vigamox) in the treatment of bacterial conjunctivitis is accompanied by cost savings. Keywords: pharmacoeconomic studies, infectious bacterial conjunctivitis, fluoroquinolones, moxifloxacin, levofloxacin, ciprofloxacin, ofloxacin, analysis of the «cost-benefit», “budget impact» analysis.
Summary: The paper presents the basic methodology for the conduct of analysis of «cost-effectiveness» and incremental analysis of «cost-effectiveness». Among other aspects, the mathematical apparatus of these species of pharmacoeconomic analysis is discussed, their semantic content is described. In the scopes of the paper we focus on the order of these types of analysis, with a brief description of each stage and its features. In particular, the requirements of the selection of compared alternatives are illustrated, as well as the importance of the selection of effectiveness criterion and types of accounted costs are stressed. The approach toward the results in the frames of each considered types of pharmacoeconomic analysis is described in details. In conclusion, a detailed graphic of the algorithm on the described types of the analysis is illustrated. Keywords: Pharmacoeconomics, cost-effectiveness/efficacy, methodology of pharmacoeconomic analysis, incremental cost-effectiveness ratio, threshold of willingness-to-pay, interpretation of results of the (incremental) “costeffectiveness” analysis, decision-making in the health system
Summary: Pharmacoeconomic analysis is a flexible tool for the decision-making on different levels in the healthcare system: from the individual patient level to the regional and federal levels. The actuality of such an analysis becomes more and more apparent in the healthcare marked by the annual increase in the implemented and published studies in this area. However, such an increase in evaluations doesn’t guarantee the proportional growth in terms of their quality and complexity. This article focuses on the opportunities of pharmacoeconomic researches, as well as on the usual inaccuracies in the pharmacoeconomic studies in Russia.
Summary: Modern health care and pharmaceutical industry can not be imagined without pharmacoeconomic studies, the results of which can justify the inclusion of medicines in the programs of medical care and prevention on different levels, as well as the conscious approach to the choice of health technologies in terms of the rational decision-making. Keywords: Congress with international participation «Development of pharmacoeconomics and pharmacoepidemiology in the Russian Federation», pharmacoeconomics, pharmacoepidemiology, Rostov-on-Don.